Oppenheimer Asset Management Inc. Ligand Pharmaceuticals Inc Transaction History

Oppenheimer Asset Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $650,363 - $1.41 Million	-6,535 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$80.55 - $106.05 $7,732 - $10,180	96 Added 1.49%	6,535 $650,000
Q3 2020 Nov 13, 2020	BUY	$89.56 - $126.72 $101,023 - $142,940	1,128 Added 21.24%	6,439 $614,000
Q2 2020 Aug 11, 2020	BUY	$68.28 - $123.65 $87,466 - $158,395	1,281 Added 31.79%	5,311 $594,000
Q1 2020 May 08, 2020	BUY	$63.37 - $107.88 $255,381 - $434,756	4,030 New	4,030 $293,000
Q3 2019 Oct 31, 2019	SELL	$86.25 - $120.16 $69,776 - $97,209	-809 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$107.38 - $129.34 $7,946 - $9,571	-74 Reduced 8.38%	809 $93,000
Q1 2019 Apr 24, 2019	SELL	$105.93 - $142.47 $23,728 - $31,913	-224 Reduced 20.23%	883 $111,000
Q4 2018 Jan 30, 2019	BUY	$128.36 - $272.13 $142,094 - $301,247	1,107 New	1,107 $150,000
Q4 2017 Feb 07, 2018	SELL	$128.36 - $147.04 $38,251 - $43,817	-298 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $36,031 - $41,106	298	298 $41,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.